In this issue:
Rucaparib for metastatic prostate cancer
IHC markers of radiation response and prognosis
Chemohormonal therapy vs extended PLND
Uncontrolled cardiovascular risk factors with prostate cancer
Healthy lifestyle in men at increased genetic risk for prostate cancer
SRT + enzalutamide for PSA recurrent prostate cancer
Nomogram for predicting positive PSMA/PET scan after recurrence
Darolutamide effects on local urinary and bowel symptoms
Long-term outcomes following AS of low-grade prostate cancer
Nadir PSA as an independent predictor of survival outcomes
Please login below to download this issue (PDF)